Prosecution Insights
Last updated: November 10, 2026
Application No. 18/456,972

ANTI-THYMOCYTE GLOBULIN

Final Rejection §102§103
Filed
Aug 28, 2023
Priority
Feb 12, 2020 — provisional 62/975,649 +1 more
Examiner
FONTAINHAS, AURORA M
Art Unit
1675
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sab LLC
OA Round
2 (Final)
38%
Grant Probability
At Risk
3-4
OA Rounds
1m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants only 38% of cases
38%
Career Allowance Rate
189 granted / 500 resolved
-22.2% vs TC avg
Strong +50% interview lift
Without
With
+49.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
36 currently pending
Career history
547
Total Applications
across all art units

Statute-Specific Performance

§101
9.7%
-30.3% vs TC avg
§103
31.4%
-8.6% vs TC avg
§102
14.1%
-25.9% vs TC avg
§112
25.0%
-15.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 500 resolved cases

Office Action

§102 §103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-5 and new claims 6-17 are under consideration in the instant Office Action. Withdrawn Objections and Rejections The objection to the specification is withdrawn in view of newly amended specification. The objection to claim 2 is withdrawn in view of newly amended claims. The rejection of claim 2 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite is withdrawn in view of newly amended claims. Modified Rejections Necessitated by Amendment Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-3 and new claims 7-11, 13 and 17 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kacskovics et al., WO2015/036004 (IDS). Kacskovics teaches methods of producing anti-thymocyte globulin (ATG). Kacskovics teaches polyclonal anti-thymocyte globulin produced in horse, goats and cows (aka bovine, see page 1, 2nd paragraph, page 11, 3rd paragraph, and page 9, 1st paragraph) and reads on instant claim 1. Kacskovics teaches that the animals are immunized with human thymocytes (see page 1, 2nd paragraph) and reads on instant claims 1-3. Kacskovics teaches administering thymocytes 2 or more time and up to 4 times (see page 13, 2nd paragraph) and reads on instant claim 2. Kacskovics teaches that this method produces immunoglobulin G (IgG) antibodies (see abstract and page 1, 1st paragraph) and reads on instant claim 3. Kacskovics teaches methods on how to produce fully human antibodies for ATG (see paragraph spanning page 20-21) and reads on instant claims 1-3. Kacskovics teaches using human thymocyte cells at 10ml solution at 7x109 cells (see page 46, 13.1) and reads on the about 1 x109 cells per ml since the concentration is about 0.7 x109 cells per ml as now required in instant claim 1. Kacskovics teaches that these cells are fresh and a live and never have been frozen as required in instant claims 7-8. Kacskovics teaches administering the human thymocytes subcutaneously (see bottom of page 13) and reads on instant claim 9. Kacskovics teaches using adjuvant with the thymocytes and that these include Freund's complete adjuvant ("FCA"), Freund's incomplete adjuvant ("FIA"), mineral gels (e.g., aluminum hydroxide), or TLR agonists, e.g. TLR-7/8, TLR-9 or TLR-10 agonists (see page 14, 2nd paragraph) and reads on instant claims 10-11. Kacskovics teaches the ATG composition, which is made up of immunoglobulins, is harvested and purified (see pages 23 and 43) and reads on instant claims 1, 13 and 17. Kacskovics teaches obtaining immunoglobulin fractions by extraction of the anti-thymocyte immunoglobulins from the animals blood from the first mammal's immune body fluid and using hemadsorption, which is the adsorption on human red blood cells, to eliminate e.g. anti-human erythrocyte immunoglobulins (see bottom of page 21) and reads on instant claims 13 and 17. The blood sample reads on the plasma requirement of claim 1 since blood includes plasma. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-5 and new claims 7-11, 13 and 17 are rejected under 35 U.S.C. 103 as being unpatentable over Kacskovics et al., WO2015/036004 (IDS) as applied to claims 1-3 and new claims 7-11, 13 and 17 above, and further in view of Matsushita et al., 2015 (IDS). See Kacskovics, as discussed above. While Kacskovics teaches a transgenic ungulate to produce a polyclonal human anti-thymocyte globulin (ATC), Kacskovics fails to specifically teach the genes encoding the transgenic ungulate as required in instant claims 4-5. Matsushita teaches transgenic ungulates to produce large-scale production of fully human IgG (hIgG) or human polyclonal antibodies (see abstract) as in instant claim 1. Matsushita teaches human IgG1 class switch regulatory elements were subjected to site-specific genomic chimerization on human artificial chromosome (HAC) vectors to further enhance hIgG expression and improve hIgG subclass distribution in cattle wherein these species-specific modifications in a chromosome scale resulted in much higher production levels of fully hIgG of up to 15 g/L in sera or plasma, the highest ever reported for a transgenic animal system (see abstract and page 2/30, 4th paragraph) as in instant claim 4. Matsushita teaches that the new HAC vectors in which the hIGHG1 gene class switch regulatory element, human Iγ1-Sγ1 (hIγ1-hSγ1) were bovinized (human sequences were replaced with bovine sequences; see page 3/30 1st paragraph) as required in instant claim 5. Matsushita teaches that transchromosomic (Tc) cattle containing engineered HAC vectors generated human polyclonal Abs with high titers against human-origin antigens following immunization (see abstract). Matsushita does not specifically teach producing the ATG of instant claim 1. It would have been prima facie obvious to the person of ordinary skill in the art to arrive at the claimed invention from the disclosures of Kacskovics and Matsushita. The person of ordinary skill in the art would have been motivated to make and use the invention as claimed because Matsushita teaches that transchromosomic (Tc) cattle containing engineered HAC vectors generated human polyclonal Abs with high titers against human-origin antigens following immunization. One of ordinary skill in the art would use the ungulate transgenic model to produce the ATG as taught by Kacskovics to increase the production level of these polyclonal antibodies for human therapy and also overcome severe side effects such as allergic reactions (see page 2/30, 1st paragraph). The person of ordinary skill in the art would have had a reasonable expectation of success based on the cumulative disclosures of these prior art references. Claims 1-5 and new claims 6-17 are rejected under 35 U.S.C. 103 as being unpatentable over Kacskovics et al., WO2015/036004 (IDS) and Matsushita et al., 2015 (IDS) in view of Hooper et al., US2017/0233459 (2/24/2026 PTO-892). See Kacskovics and Matsushita, as discussed above. Neither reference teaches the limitations of new claims 13-16. Hooper teaches methods of producing human polyclonal antibodies by immunizing transchromosomal ungulate animals [0004-0005] as required in instant claim 1. Hooper teaches vaccinating the ungulate animal every 3-4 week intervals with a vaccine with an adjuvant wherein it is an oil adjuvant, Montanide ISA 206 (which is a water-in-oil-in-water (w/o/w) type of emulsion), (see [0145] and Table 1) as required in instant claims 10-12. Hooper teaches purification of fully human IgG by collecting plasma and using caprylic acid to fractionate the plasm, followed by filtration steps using a depth filter device to remove non - IgG proteins from bovine plasma and further purified by using human IgG light chain kappa specific affinity chromatography followed by a second purification using bovine IgG heavy chain specific affinity chromatography (see [0146-0147]; [0195-0196]) as required in instant claims 1 and 13-16. It would have been prima facie obvious to the person of ordinary skill in the art to arrive at the claimed invention from the disclosures of Kacskovics, Matsushita and Hooper. The person of ordinary skill in the art would have been motivated to make and use the invention as claimed because Hooper teaches producing human antibodies in an ungulate animal and that they are successful in vaccinating the animal at 3-4 week intervals and one would use the method of purification taught by Hooper since it will produce a pure human antibody product which would be safer for use in the target subject, humans. One of ordinary skill in the art would use the ungulate transgenic model to produce the ATG as taught by Kacskovics to increase the production level of these polyclonal antibodies for human therapy and also overcome severe side effects such as allergic reactions (see page 2/30, 1st paragraph). Finally, Kacskovics teaches using human thymocyte cells at 10ml of cell solution at 7x109 cells (see page 46, 13.1) and reads on the about 1 x109 cells per ml since the concentration is about 0.7 x109 cells per ml. New claim 6 call for higher concentrations which would be achieved since Kacskovics teaches centrifuging these cell and therefore concentrating the cells and would produce the required doses through routine optimization of the method and purification concentration. The person of ordinary skill in the art would have had a reasonable expectation of success based on the cumulative disclosures of these prior art references. Response to Arguments Applicant's arguments filed 7/24/2026 have been fully considered but they are not persuasive. Applicant argues that the Kacskovics reference fails to teach the new limitation of cell dosages of instant claim 1. This is not found persuasive as already show above that the Kacskovics does indeed meet the new requirement. Further, Kacskovics also meets the other new limitations as set forth above in the anticipatory rejection. All new limitations that were not met by the prior art are taught by the Hooper reference as set forth above. Therefore, the arguments are not found persuasive and the claims stand rejected for the rejections set forth above. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Advisory Information Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.Any inquiry concerning this communication or earlier communications from the examiner should be directed to AURORA M. FONTAINHAS whose telephone number is 571-272-2952. The examiner can normally be reached on Monday - Friday (8AM - 4PM). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Stucker can be reached on (571)272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. /AURORA M FONTAINHAS/Primary Examiner, Art Unit 1675
Read full office action

Prosecution Timeline

Aug 28, 2023
Application Filed
Feb 24, 2026
Non-Final Rejection mailed — §102, §103
Jul 24, 2026
Response Filed
Oct 26, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780947
Antibody Binding to CHI3L1 for Treating Cancer
2y 7m to grant Granted Nov 03, 2026
Patent 12767710
METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF HUMANIZED CONFORMATION-SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
3y 9m to grant Granted Oct 20, 2026
Patent 12760121
HUMANIZED ANTIBODIES AGAINST IRHOM2
3y 1m to grant Granted Oct 13, 2026
Patent 12735676
AFFINITY-TAGGED PHOTOSWITCHES AND METHODS OF USE THEREOF
6y 6m to grant Granted Sep 15, 2026
Patent 12673119
NON-HUMAN MAMMAL MODEL OF HUMAN DEGENERATIVE DISORDER, USES THEREOF, AND METHOD OF TREATING HUMAN DEGENERATIVE DISORDER
3y 5m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
38%
Grant Probability
87%
With Interview (+49.6%)
3y 3m (~1m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 500 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month